These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 2372769)

  • 21. Follow-up of patients with localized breast cancer and first indicators of advanced breast cancer recurrence: A retrospective study.
    Viot J; Bachour M; Meurisse A; Pivot X; Fiteni F
    Breast; 2017 Aug; 34():53-57. PubMed ID: 28505557
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Disordered nocturnal prolactin regulation in women with breast cancer.
    Malarkey WB; Schroeder LL; Stevens VC; James AG; Lanese RR
    Cancer Res; 1977 Dec; 37(12):4650-4. PubMed ID: 922745
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prolactin concentrations in patients with breast cancer.
    Franks S; Ralphs DN; Seagroatt V; Jacobs HS
    Br Med J; 1974 Nov; 4(5940):320-1. PubMed ID: 4434088
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Clinical course of recurrent and metastatic disease in breast cancer].
    Koffmann B; Baez MR
    Rev Med Chil; 1991 Apr; 119(4):423-7. PubMed ID: 1842986
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Use of posttreatment imaging and biomarker testing for survivors of breast cancer.
    Barton MK
    CA Cancer J Clin; 2016 May; 66(3):175-6. PubMed ID: 26991239
    [No Abstract]   [Full Text] [Related]  

  • 26. Application of mammary serum antigen assay in the management of breast cancer: a preliminary report.
    Tjandra JJ; Russell IS; Collins JP; Stacker SA; McKenzie IF
    Br J Surg; 1988 Aug; 75(8):811-7. PubMed ID: 3048535
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical relevance of soluble c-erbB-2 for patients with metastatic breast cancer predicting the response to second-line hormone or chemotherapy.
    Classen S; Kopp R; Possinger K; Weidenhagen R; Eiermann W; Wilmanns W
    Tumour Biol; 2002; 23(2):70-5. PubMed ID: 12065844
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The pattern of metastases in Nigerian breast cancer patients.
    Ketiku KK
    Clin Radiol; 1986 Nov; 37(6):563-5. PubMed ID: 3791853
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Correlations between prolactin and somatotropic hormone in human breast cancer].
    Larrad Jiménez A; Caballero Asensi A; Estévez Molina M
    Rev Esp Oncol; 1980; 27(1):29-52. PubMed ID: 7209107
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Correlations between PRL and 17-beta-E in human breast cancer].
    Larrad Jiménez A; Ruiz-Tartas A; Zapatero Gaviria J; López Lazareno N
    Rev Esp Oncol; 1984; 31(2):279-87. PubMed ID: 6549590
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Treatment outcomes and clinicopathologic characteristics of advanced triple-negative breast cancer patients].
    Zhang P; Xu BH; Ma F; Li Q; Yuan P; Wang JY; Zhang P
    Zhonghua Zhong Liu Za Zhi; 2011 May; 33(5):381-4. PubMed ID: 21875471
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Elevated level of cell-free plasma DNA is associated with advanced-stage breast cancer and metastasis.
    Nicolini C; Ens C; Cerutti T; Roehe AV; Agnes G; Damin AP; Alexandre CO
    Clin Chem Lab Med; 2013 Jun; 51(11):e277-8. PubMed ID: 23807672
    [No Abstract]   [Full Text] [Related]  

  • 33. CA 15-3 in patients with locoregional and metastatic breast carcinoma.
    Geraghty JG; Coveney EC; Sherry F; O'Higgins NJ; Duffy MJ
    Cancer; 1992 Dec; 70(12):2831-4. PubMed ID: 1451063
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prolactin as a local growth promoter in patients with breast cancer: GCRI experience.
    Bhatavdekar JM; Patel DD; Shah NG; Vora HH; Suthar TP; Ghosh N; Chikhlikar PR; Trivedi TI
    Eur J Surg Oncol; 2000 Sep; 26(6):540-7. PubMed ID: 11034803
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Plasma prolactin levels in women at postmenopausal age with a family history of breast cancer or a prescription for antihypertensive Rauwolfia treatment.
    de Waard F; Kwa HG; Poortman J
    Oncology; 1980; 37(1):33-6. PubMed ID: 7350553
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Circulating tumour cell-derived plastin3 is a novel marker for predicting long-term prognosis in patients with breast cancer.
    Ueo H; Sugimachi K; Gorges TM; Bartkowiak K; Yokobori T; Müller V; Shinden Y; Ueda M; Ueo H; Mori M; Kuwano H; Maehara Y; Ohno S; Pantel K; Mimori K
    Br J Cancer; 2015 Apr; 112(9):1519-26. PubMed ID: 25880010
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prognostic significance of serum prolactin levels in advanced breast cancer.
    Dowsett M; McGarrick GE; Harris AL; Coombes RC; Smith IE; Jeffcoate SL
    Br J Cancer; 1983 Jun; 47(6):763-9. PubMed ID: 6860546
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Role and mechanism of action of tamoxifen in premenopausal women with metastatic breast carcinoma.
    Sawka CA; Pritchard KI; Paterson AH; Sutherland DJ; Thomson DB; Shelley WE; Myers RE; Mobbs BG; Malkin A; Meakin JW
    Cancer Res; 1986 Jun; 46(6):3152-6. PubMed ID: 3084082
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Reproductive factors and family history of breast cancer in relation to plasma prolactin levels in premenopausal and postmenopausal women.
    Eliassen AH; Tworoger SS; Hankinson SE
    Int J Cancer; 2007 Apr; 120(7):1536-41. PubMed ID: 17211859
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The value of the tumor marker CA 15-3 in diagnosing and monitoring breast cancer. A comparative study with carcinoembryonic antigen.
    Safi F; Kohler I; Röttinger E; Beger H
    Cancer; 1991 Aug; 68(3):574-82. PubMed ID: 2065278
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.